Menu

Final Nail Hammered into NgAgo Coffin

The paper describing the gene-editing method is retracted.

Aug 3, 2017
Kerry Grens

ISTOCK, FSTOP123Following an editorial expression of concern last year, the authors of a study describing a gene-editing method have retracted their paper from Nature Biotechnology. They say that despite the efforts of numerous independent laboratories, their observations could not be replicated.

The editors of Nature Biotechnology praised the process. “[I]t is the wider research community that tests methods, identifies potential sources of error, validates reagents and optimizes assays,” they wrote in an editorial. “In this case, it took dozens of dedicated individuals to work through the details of the published protocol and produce well-documented and controlled refutation studies.”

The original study claimed to have found a competitor for CRISPR genome editing. NgAgo, an Argonaut protein from archaea, could precisely disrupt specified sequences in the human genome, Chunyu Han of Hebei University of Science and Technology in Shijiazhuang, China, and colleagues reported. But replication attempts failed.

“We are therefore retracting our initial report at this time to maintain the integrity of the scientific record,” Han’s team wrote in the retraction notice. “We nevertheless continue to investigate the reasons for this lack of reproducibility with the aim of providing an optimized protocol.”

See “Scientists Can’t Replicate Gene-Editing Method

As Nature points out, Danish biomedical company Novozymes paid an undisclosed amount of money to partner with Hebei. “Scientific research takes time and we’ll continue to look for any technological advances, NgAgo included, that can have a positive impact on our work,” Dongyi Chen, Novozymes’s press manager, tells Nature.

July 2019

On Target

Researchers strive to make individualized medicine a reality

Marketplace

Sponsored Product Updates

Overcoming the Efficiency Challenge in Clinical NGS
Overcoming the Efficiency Challenge in Clinical NGS
Download this white paper to see how an ECS lab serving a network of more than 10,000 healthcare providers integrated QIAGEN Clinical Insight (QCI) Interpret to significantly reduce manual variant curation efforts and increase workflow efficiency by 80%!
Veravas Launches Product Portfolio to Mitigate Biotin Interference and Improve Diagnostic Assay Accuracy
Veravas Launches Product Portfolio to Mitigate Biotin Interference and Improve Diagnostic Assay Accuracy
Veravas, Inc., an emerging diagnostic company, launched a portfolio of products that can improve the accuracy of current diagnostic test results by helping laboratory professionals detect and manage biotin interference in patient samples with VeraTest Biotin and VeraPrep Biotin.
New Data on Circulating Tumor DNA as a Biomarker for Detecting Cancer Progression Presented at 2019 ASCO Annual Meeting
New Data on Circulating Tumor DNA as a Biomarker for Detecting Cancer Progression Presented at 2019 ASCO Annual Meeting
Scientists presented more than 30 abstracts featuring Bio-Rad’s Droplet Digital PCR (ddPCR) technology at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, May 31–June 4.
BellBrook Labs Receives NIH Grant for the Discovery of cGAS Inhibitors to Treat Autoimmune Diseases
BellBrook Labs Receives NIH Grant for the Discovery of cGAS Inhibitors to Treat Autoimmune Diseases
The National Institute Of Allergy And Infectious Disease recently awarded BellBrook Labs a $300,000 Small Business Innovative Research (SBIR) grant to develop novel inhibitors for the target cyclic GAMP Synthase (cGAS). The grant will be used to accelerate the discovery of new treatments for autoimmune diseases by targeting the cGAS-STING pathway.